Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy

A legfontosabb adatok

Ki végzi
Istanbul University
Hol
Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
44 fő vett részt
Kezdés
2023. jún. 1.
Befejezés
2026. febr. 15.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A regiszteradat frissítve
2026. július 13.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Having a diagnosis of primary membranous nephropathy (patient group)
  • Having a diagnosis of primary IgA nephropathy (diseased control group)
  • Being healthy (healthy control group)
  • Agreeing to participate in the research (informed consent)

Ki nem vehet részt

  • Refusing to participate in the research

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN). A search for disease-related circulating antibodies [anti-phospholipase A2 receptor antibody (anti-PLA2R) and anti-thrombospondin type 1 domain-containing 7A antibody (anti-THSD7A)] in patients' sera is also planned.

A teljes eredeti leírásKevesebb

The main questions to answer are:

1. What is the relationship of these cell populations and their distribution during follow-up with treatment, treatment responses, and relapses? 2. What is the relationship of the cell populations with anti-PLA2R (or anti-THSD7A) antibody levels?

Participants will provide peripheral venous blood samples at pre-designated regular intervals.

The research team will compare results of the primary MN group with two control groups (IgA nephropathy and healthy volunteer groups) to see if the findings are specific for primary MN.

A vizsgálat 3 csoportja

  • Study Group (Primary Membranous Nephropathy)

    Patients with biopsy-proven primary membranous nephropathy will be included (n=18). Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment. In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX. If relapse occurs, sampling will be done regardless of the timing. Treatment decisions will solely be made in line with the guidelines, and there will be no intervention.

  • Control Group 1 (IgA Nephropathy)

    After the patient group sampling is completed, a diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=12). Samples will be collected from the patients for one time only (cross-sectional sampling).

  • Control Group 2 (Healthy Volunteers)

    After the patient group sampling is completed, a healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=14). Samples will be collected from healthy volunteers for one time only (cross-sectional sampling).

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Analysis of T- and B-Cell Subpopulations in Patients With Primary Membranous Nephropathy
A regiszteradat frissítve
2026. július 13.